Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy-Reference-Cited by-同舟云学术

Survival and prognostic factors for patients with melanoma brain metastases in the era of modern systemic therapy

Published:2018-01-10 Issue:4 Volume:31 Page:509-515
ISSN:1755-1471
Container-title:Pigment Cell & Melanoma Research
language:en
Short-container-title:Pigment Cell Melanoma Res.

Author:

Tio Martin¹^ORCID,Wang Xuan²,Carlino Matteo S.³⁴⁵,Shivalingam Brindha³⁵⁶⁷,Fogarty Gerald B.³⁵⁷⁸,Guminski Alexander D.¹³⁵⁷,Lo Serigne³⁵,Hong Angela M.³⁵⁷⁸,Menzies Alexander M.¹³⁵⁷,Long Georgina V.¹³⁵⁷

Affiliation:

1. Department of Medical Oncology; Royal North Shore Hospital; St Leonards NSW Australia

2. Peking University Cancer Hospital and Institute; Beijing China

3. Melanoma Institute Australia; North Sydney NSW Australia

4. Crown Princess Mary Cancer Centre Westmead; Sydney NSW Australia

5. Sydney Medical School; The University of Sydney; Camperdown NSW Australia

6. Royal Prince Alfred Hospital; Camperdown NSW Australia

7. Mater Hospital; North Sydney NSW Australia

8. Genesis Cancer Care; Mater Radiation Oncology; North Sydney NSW Australia

Funder

Cancer Institute NSW

Publisher

Wiley

Subject

Dermatology,General Biochemistry, Genetics and Molecular Biology,Oncology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/pcmr.12682/fullpdf

Reference36 articles.

1. Clinical outcomes of melanoma metastases treated with stereotactic radiosurgery and anti-PD1 therapy, anti-CTLA-4 therapy, BRAF/MEK inhibitors, BRAF inhibitor, or conventional chemotherapy;Ahmed;Annals of Oncology,2016

2. Incidence proportions of brain metastases in patients diagnosed (1973-2001) in the Metropolitan Detroit Cancer Surveillance System;Barnholtz-Sloan;Journal of Clinical Oncology,2004

3. Predictors and survival in patients with melanoma brain metastases;Bottoni;Medical Oncology,2013

4. Postoperative stereotactic radiosurgery compared with whole brain radiotherapy for resected metastatic brain disease (NCCTG N107C/CEC-3): A multicentre, randomised, controlled, phase 3 trial;Brown;The Lancet. Oncology,2017

5. Correlation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma;Carlino;British Journal of Cancer,2014

Cited by 36 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Melanoma Brain Metastasis;Hematology/Oncology Clinics of North America;2024-10

2. Compromised Blood-Brain Barrier Junctions Enhance Melanoma Cell Intercalation and Extravasation;Cancers;2023-10-20

3. Estimating survival in patients with melanoma brain metastases: prognostic value of lactate dehydrogenase;Melanoma Research;2023-07-03

4. Proteomic profiling of cutaneous melanoma explains the aggressiveness of distant organ metastasis;Experimental Dermatology;2023-04-21

5. Impact of whole brain radiotherapy after treatment of melanoma brain metastases on an individual’s employment and household income;2023-03-31